8-K: INmune Bio Expands Stem Cell Collaboration with Anthony Nolan

INmune Bio Inc. and Anthony Nolan have entered into an amended and restated Material Transfer and License Agreement to secure long-term supply of umbilical cord tissue for INmune Bio's CORDStrom platform.

Summary

• INmune Bio Inc. has entered into an amended and restated Material Transfer and License Agreement with its wholly-owned subsidiary, INmune Bio International, and Anthony Nolan.
• This agreement amends and restates a prior agreement from November 29, 2017, as amended on March 21, 2023.
• The company will be jointly and severally liable with its subsidiary for payment obligations under the royalty provisions.
• The expanded collaboration ensures a long-term supply of high-quality umbilical cord tissue for INmune Bio's CORDStrom platform.
• Anthony Nolan will receive a 2% royalty on net sales of each Product, capped annually at £5,000,000, and fees for Cell and Gene Therapies Services.
• The agreement includes provisions for traceability and quality management, adhering to Good Manufacturing Practice (GMP) and Human Tissue Authority (HTA) standards.
• The agreement is effective April 29, 2026, and has a term of ten years from the date of First Commercial Sale.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it solidifies a crucial supply chain for INmune Bio's CORDStrom platform and expands its therapeutic targets, indicating strategic progress.

Positives

• Secures long-term supply of critical starting material (umbilical cord tissue) for INmune Bio's CORDStrom platform.
• Establishes a clear royalty structure (2% of net sales) with an annual cap (£5,000,000) for Anthony Nolan.
• Incorporates robust traceability and quality management standards (GMP, HTA) into the collaboration.
• INmune Bio Inc. is now a direct party to the agreement, providing joint and several liability for payment obligations.
• The CORDStrom platform is described as the industry's most advanced Mesenchymal Stromal Cell (MSC) technology, designed for consistent, scalable, off-the-shelf therapies.
• The collaboration aims to address the MSC consistency challenge by utilizing tested, screened, and pooled umbilical cord-derived MSCs.
• The expanded collaboration targets high-impact indications including Recessive Dystrophic Epidermolysis Bullosa (RDEB), Oncology (solid tumors), Osteoarthritis, and Systemic Lupus Erythematosus (SLE).

Negatives

• Anthony Nolan is entitled to a royalty capped at £5,000,000 per annum, which could limit their upside if sales exceed this cap significantly.
• The agreement allows for termination by either party with notice (30 days for INmune Bio, 6 months for Anthony Nolan), introducing potential instability.
• INmune Bio is responsible for ensuring Service Providers comply with the agreement and is liable for their acts and omissions.
• The agreement is governed by English law and the courts of England and Wales have exclusive jurisdiction, which may be less convenient for a US-based company.

Risks

• Potential for disputes regarding the definition of 'Net Sales' or the calculation of royalties.
• Risk of supply disruptions if Anthony Nolan cannot identify suitable donors or provide materials meeting acceptance criteria.
• The agreement can be terminated by either party under specific 'Event of Default' conditions, which could impact INmune Bio's supply chain.
• INmune Bio's reliance on Anthony Nolan for critical starting materials creates a dependency risk.
• Potential for regulatory changes impacting the handling or use of umbilical cord tissue and derived cells.
• The agreement's term is 10 years from the First Commercial Sale, but early termination clauses introduce uncertainty.
• INmune Bio's liability for acts and omissions of its Service Providers and Commercialisation Partners could lead to unforeseen costs or legal issues.

Future Outlook

The expanded collaboration secures the long-term provision of umbilical cord tissue to power INmune Bio's CORDStrom platform, targeting indications such as RDEB, oncology, osteoarthritis, and SLE. The agreement is structured for a term of ten years from the date of First Commercial Sale, with provisions for CPI-linked fee increases starting in 2027.

Management Comments

• "We view CORDStrom as a tremendous platform that finally solves the fundamental challenge of understanding MSCs as a drug. By partnering with Anthony Nolan's Cell Therapy & Laboratory Services, we are combining the most advanced MSC cell platform with the most reliable source of cellular starting material. This collaboration allows us to move beyond the limitations of traditional cell therapy and provide consistent, high-potency treatments for patients suffering from RDEB, cancer, and chronic inflammatory conditions."
• "We remain hugely grateful to the volunteer donors who provide the UC for our program and who consent to UK and US testing to make CORDStrom universally available."
• "This partnership with our Cell Therapy and Laboratory Services allows our donor materials to reach their full potential within a cutting-edge manufacturing platform, facilitating the development of medicinal products that meet the highest ethical and regulatory standards for patients worldwide."

Industry Context

StockSavvy.ai notes that this strategic expansion by INmune Bio Inc. with Anthony Nolan addresses a critical industry challenge in cell therapy: the inconsistency and variability of Mesenchymal Stromal Cells (MSCs). By leveraging Anthony Nolan's established infrastructure and INmune Bio's CORDStrom platform, the companies aim to create standardized, scalable MSC-based therapies, positioning INmune Bio to potentially capture significant market share in areas with high unmet needs like RDEB, oncology, and inflammatory diseases.

Comparison to Industry Standards

• The agreement emphasizes adherence to Good Manufacturing Practice (GMP) and Human Tissue Authority (HTA) standards, which are industry benchmarks for cell and tissue-based therapies.
• The CORDStrom platform's approach of testing, screening, and pooling umbilical cord-derived MSCs to create standardized MSC Banks is designed to overcome donor variability, a common hurdle in the MSC therapeutic field.
• The focus on specific indications like RDEB, oncology, osteoarthritis, and SLE aligns with current trends in regenerative medicine and targeted therapies.
• The collaboration's aim to produce 'off-the-shelf' cellular therapies is a key industry goal, moving away from patient-specific treatments towards more scalable and accessible options.

Stakeholder Impact

• Shareholders: Potential positive impact due to secured supply chain for a key platform and expansion into new therapeutic areas, which could lead to future revenue growth.
• Patients: Potential benefit from the development of new, consistent, and scalable cell therapies for serious conditions like RDEB, cancer, and inflammatory diseases.
• Anthony Nolan: Receives a 2% royalty on net sales, providing a revenue stream to support its charitable mission, capped annually.
• Employees: Continued employment opportunities within INmune Bio and Anthony Nolan related to the ongoing development and management of the collaboration.

Next Steps

• Continue development of CORDStrom platform therapies for RDEB, oncology, osteoarthritis, and SLE.
• Ensure ongoing compliance with GMP and HTA standards.
• Manage royalty payments and reporting as per the agreement terms.
• Potentially explore further indications or applications for the CORDStrom platform.

Key Dates

Recommendation

The filing details a material definitive agreement that formalizes and expands an existing collaboration, securing a critical supply chain for INmune Bio's CORDStrom platform. While positive for long-term strategy and pipeline development, it does not present immediate, significant financial results or breakthroughs that would warrant a strong buy or sell recommendation. It represents expected operational progress.

Keywords

INmune Bio, Anthony Nolan, CORDStrom, Mesenchymal Stromal Cells, MSC, Umbilical Cord Tissue, Material Transfer Agreement, License Agreement